The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Today, cancer stage and tumor size tell which patients will receive adjuvant chemotherapy. But the rise of biomarker testing ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

CHICAGO -- Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to ...

A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...